A5082659622- Cancer Treatment and Pharmacology
- Colorectal Cancer Treatments and Studies
- Hepatocellular Carcinoma Treatment and Prognosis
- Lung Cancer Research Studies
- Lung Cancer Treatments and Mutations
- Head and Neck Cancer Studies
- Pharmacogenetics and Drug Metabolism
- Cancer therapeutics and mechanisms
- Drug Transport and Resistance Mechanisms
- Angiogenesis and VEGF in Cancer
- Cancer, Hypoxia, and Metabolism
- Health Systems, Economic Evaluations, Quality of Life
- Neuroendocrine Tumor Research Advances
- HER2/EGFR in Cancer Research
- Vascular Tumors and Angiosarcomas
- Lymphoma Diagnosis and Treatment
- Cholangiocarcinoma and Gallbladder Cancer Studies
- RNA modifications and cancer
- Ferroptosis and cancer prognosis
- Axon Guidance and Neuronal Signaling
- Cancer Cells and Metastasis
- Pleural and Pulmonary Diseases
- Multiple Myeloma Research and Treatments
- Cardiac tumors and thrombi
- Neutropenia and Cancer Infections
Athenex (United States)
2016-2024
National Taiwan University Hospital
2006-2023
University of Malaya
2021
Toronto Public Health
2014
National Taiwan University
1998-2013
National Yang Ming Chiao Tung University
1996-2012
Institute of Statistical Science, Academia Sinica
2012
Taichung Veterans General Hospital
2006-2012
Institutes of Science and Development
2007
Institute of Biomedical Sciences, Academia Sinica
1994-2006
Current staging methods are inadequate for predicting the outcome of treatment non–small-cell lung cancer (NSCLC). We developed a five-gene signature that is closely associated with survival patients NSCLC.
Patients with non-small-cell lung cancer (NSCLC) epidermal growth factor receptor (EGFR)-activating mutations have excellent response to EGFR tyrosine kinase inhibitors (TKIs), but T790M mutation accounts for most TKI drug resistance. This study used highly sensitive methods detect before and after therapy investigated the association of its frequencies clinical outcome.Direct sequencing, matrix-assisted laser desorption ionization-time flight mass spectrometry (MALDI-TOF MS) next-generation...
Although enterovirus 71 has caused epidemics associated with significant morbidity and mortality, its transmission not been thoroughly investigated.To investigate determine clinical outcomes within households.Prospective family cohort study to patients at a children's hospital in Taiwan members of these who had signs symptoms suggestive between February 2001 August 2002. Patients household underwent evaluations, virological studies, questionnaire-based interviews, were followed up for 6...
Neuropilin 1 (NRP1) is a mediator of lung branching and angiogenesis in embryonic development cancer. The role NRP1 cancer progression not fully elucidated. We investigated the invasion tumor angiogenesis, its signaling pathways, prognostic significance, therapeutic implications.Sixty patients with non-small cell (NSCLC) were studied. mRNA expression was measured using real-time quantitative reverse-transcription PCR. invasion, pathways studied stimulation by vascular endothelial growth...
PURPOSE To evaluate prospectively the efficacy of granulocyte-macrophage colony-stimulating factor (GM-CSF) in reduction chemotherapy-induced oral mucositis. PATIENTS AND METHODS Twenty patients with stage IV squamous cell carcinoma head and neck were studied. Two-cycles (periods) identical doses cisplatin, fluorouracil (5-FU), leucovorin (PFL) chemotherapy cisplatin 20 mg/m2/d, 5-FU 800 90 mg/m2/d by 96-hour continuous intravenous infusion every 3 weeks given to each patient. After PFL...
Rationale: Triggering receptor expressed on myeloid cells (TREM)-1 is a molecule crucial for the triggering and amplification of inflammatory response new biomarker sepsis. Tumor-associated macrophages inflammation in tumor microenvironment are also involved cancer progression.Objectives: To determine role TREM-1 tumor-associated macrophage progression.Methods: Using ELISA Western blot, we measured soluble levels 65 pleural effusions various etiologies. We evaluated TREM-1–positive by...
We previously identified DnaJ-like heat shock protein (HLJ1) as a gene associated with tumor invasion. Here, we investigated the clinical significance of HLJ1 expression in non-small-cell lung cancer (NSCLC) patients and its role progression.We induced overexpression or knockdown human adenocarcinoma CL1-5 cells analyzed cell proliferation, anchorage-independent growth, vivo tumorigenesis, motility, invasion, cycle progression. Expression genes that act downstream was examined by DNA...
Metastasis is a predominant cause of death in patients with cancer. It complex multistep process that needs to be better understood if we are develop new approaches managing tumor metastasis. Tumor cell invasion the local stroma suppressed by collapsin response mediator protein-1 (CRMP-1). Recently, identified long isoform CRMP-1 (LCRMP-1), expression which correlates cancer invasiveness and poor clinical outcome non-small-cell lung (NSCLC). Here, report LCRMP-1 overexpression noninvasive...
Background. Systemic disease progression occurs in the majority of patients with locally advanced nasopharyngeal carcinoma (NPC). Although a variety chemotherapeutic drugs have had tumoricidal activity, roles chemotherapy and optimal regimens must be further defined. Based on high response rates Cisplatin, 5-Fluororacil Leucovorin (PFL) squamous cell cancers head neck, we tested new outpatient PFL program NPC. Methods. Patients NPC 1) previously untreated, disease; 2) local regional...
Abstract HLJ1 is a novel tumor and invasion suppressor that inhibits tumorigenesis cancer metastasis. However, the mechanism of activation currently unclear. Here, we identify an enhancer segment in gene at −2,125 to −1,039 bp upstream transcription start site. A 50-bp element between −1,492 −1,443 minimal segment, which includes activator protein 1 (AP-1) site (−1,457 −1,451 bp), essential regulatory domain binds transcriptional factors FosB, JunB, JunD. Chromatin immunoprecipitation assays...
Hepatocellular carcinoma (HCC) is a male predominant disease and may be an androgen-dependent or androgen-responsive tumor. This Phase 11 study was designed to investigate the clinical activity toxicity of flutamide in treatment patients with advanced HCC.Thirty-two measurable HCC were studied. Flutamide, 750 mg per day, administered orally for 8 weeks. Ten died before repeat tumor measurements could performed.Twenty-two evaluable response toxicities. There no complete responses nor partial...
The aim of the present study was to investigate whether imprint cytology can improve diagnostic accuracy computed tomography-guided transthoracic core biopsy. Between October 1997 and June 2004, thoracic lesions in 622 patients underwent biopsy using 19-gauge coaxial guiding needles 20-gauge under tomography guidance. Touch histopathology were performed for all specimens. Of these lesions, 431 (74.1%) diagnosed as malignant, 151 (25.9%) benign 40 (6%) nondiagnostic. Imprint plus histology...
Abstract The development of optimized dosing regimens plays a crucial role in oncology drug development. This study focused on the population pharmacokinetic modelling and simulation docetaxel, comparing exposure oral docetaxel plus encequidar (oDox + E) with standard care intravenous (IV) regimen. aim was to evaluate feasibility oDox E as potential alternative IV docetaxel. article demonstrates an approach which aligns FDA’s Project Optimus aims improve through model informed (MIDD). key...
This is a report of phase II study megestrol acetate (160mg/day, orally) in the treatment hepatocellular carcinoma (HCC). Forty‐six patients with advanced HCC were studied and tumour response, changes appetite, bodyweight, feeling well‐being, survival toxicity evaluated. Thirty‐two able to be evaluated for response; there no complete responders or partial responders. Twelve (38%) had stable disease seven these minor response median size reduction 18%. Twenty (62%) progressive disease. Five...